"Study H9X-MC-GBGC is a Phase 3, randomized, double-blind, placebo-controlled trial withan open-label extension that investigates the effect of the addition of dulaglutide (0.75 and1.5 mg/week) or placebo weekly to metformin and/or basal insulin on change from baselinein hemoglobin A1c at 26 weeks in children and adolescents with type 2 diabetes mellitus"

drug protocol number
H9X-MC-GBGC
drug sponsor
Eli Lilly
drug study
Dulaglutide 0.75 /1.5 mg
drug trial site
King Khalid University Hospital (Riyadh), International Medical Center (Jeddah)
drug status
Ongoing
drug phase